



Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes

To the Editor:

As of 2018, the majority of Western European countries – including Spain – have lifted restrictions to therapy based on disease severity in the context of HCV infections.¹ Long overdue, most national elimination programmes now also include access to care for people who inject drugs (PWID),² who are at the core of ongoing HCV transmission.³ Macías *et al.*⁴ have recently shown in this *Journal* that high viral cure rates can be achieved in this group, hereby providing evidence that targeting PWID in treatment programmes is worthwhile. However, the extent to which such national efforts can reduce the HCV burden not only depends on the uptake into care and treatment success rates, it is also determined by the relative importance of within-country transmission and virus importation from elsewhere.

As the chronic nature of most HCV infections hampers reliably reconstructing contact networks from patient interviews, virus genetic data can be a valuable alternative source of information for elucidating the geographic history of virus lineages (e.g. 5,6). Using such data, we have recently shown that for the most prevalent subtype among PWID in Spain (40%,⁷), HCV1a, infections often link to infections abroad – in recent years >50% link to Western European countries, mostly European Union (EU) member states – as opposed to other infections within Spain.⁸ Hence, reducing HCV1a prevalence and spread across Europe will help to consolidate the impact of Spanish efforts to reduce the HCV burden.

To investigate whether this is a general pattern that also holds for the second most prevalent subtype among PWID in Spain (26.5%,⁷), HCV3a, we analysed newly generated HCV3a genome data covering parts of the NS5A and/or NS5B genes from 196 HCV3a-infected patients sampled between April 2014 and April 2017 across Spain (GenBank: accession numbers MN227780 – MN228016). Of the 60% for whom information on the probable route of transmission was available, 81.8% reported injecting drug use. These sequences were complemented with a background dataset of publicly available data from GenBank (totalling 2752 taxa), and analysed as previously described.^{5,8} The Ethics Committee of the San Cecilio Hospital, Granada, approved the study, and no informed consent was required as patient information was anonymised and de-identified prior to analysis.

As for HCV1a,⁸ we found that the transmission network size structure is not dominated by a few large exclusively Spanish transmission networks, meaning that HCV3a transmission hot spots in Spain more often bridge to networks abroad rather than being connected domestically. Whereas we previously found an increasing importance of European lineages in seeding the HCV1a epidemic in Spain,⁸ our current reconstructions showed that HCV3a virus movements from within the EU account for ~85% of all migrations towards Spain, with little fluctuation over time. The number of imported HCV3a infections per year from other EU member states – which is a lower bound estimate – has increased on average by 1 to 4 per year, totalling 125 (95% credible interval: 92–158) introductions (Fig. 1). The trend

and magnitude are similar to those for HCV1a, for which the number of lineage introductions totals 114 (95% credible interval: 72–156) (Fig. 1).

The Spanish national strategy against HCV is based on a combination of factors, including a focus on increased screening and diagnosis, enhancing the treatment infrastructure, the availability of improved therapeutic regimens and targeting the groups at highest risk of transmitting HCV, including PWID.^{9–11} Despite existing challenges and policy differences between regions, this multifactorial approach has led to Spain being one of the few countries in Europe that are reported to be on track to meet the World Health Organization HCV elimination targets by 2030.¹² As more recent subtype 1a and 3a infections are associated with illicit (injecting) drug use (e.g. 3), targeting this group that drives onwards spread, and for which Macías *et al.*⁴ have demonstrated that treatment can be highly effective, is most desirable in many countries. However, across Europe, most countries have yet to embrace the universal treatment paradigm, and even more are yet to develop and implement a national strategy towards the elimination of HCV.¹ Our current and previous results⁸ illustrate that in the absence of the latter, HCV will rapidly be re-seeded in the Spanish PWID population, challenging the long-term impact of the current Spanish intervention efforts. This demonstrates that there are beneficial scale-effects to implementing concurrent national efforts in the EU and elsewhere, without which the ultimate goal, namely eliminating HCV, will likely remain elusive.




Fig. 1. Frequent importation of HCV subtype 1a and 3a lineages into Spain mostly from other countries within the European Union. The lines correspond to the average cumulative number of introduction events for these subtypes from other countries within the European Union into Spain, with the shaded areas indicating the uncertainty (95% credible interval). Grey colors pertain to subtype 1a, and blue colors to subtype 3a.

Keywords: HCV; PWID; Elimination; National strategy; Spain; European Union.

Financial support

This work was supported by the Bijzonder Onderzoeksfonds KU Leuven (BOF) No. OT/14/115, the Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO) (projects G066215N and GOE2317N, and a postdoctoral mandate to Bram Vrancken), and by grants from Fondo de Investigacion Sanitaria (www.isciii.es) (PI15/00713), Plan Nacional de I + D + I, Fondo Europeo de Desarrollo Regional-FEDER (www.redes/redes/inicio) (RD16/0025/0040) and GEHEP-SEIMC (GEHEP-004). Part of the computational resources and services were provided by the Hercules Foundation and the Flemish Government – department EWI-FWO Krediet aan Navorsers (Theys, KAN2012 1.2.249.12).

Conflict of interest

All authors have nothing to disclose, except for Federico Garcia, Joaquin Anton-Basantas and Miguel Angel Von Wichmann who report grants and personal fees from Viiv Healthcare, personal fees from Gilead, personal fees from Abbvie and/or personal fees from MSD and/or personal fees from Janssen, outside the submitted work; and Anne-Mieke Vandamme who reports grants from the Research Foundation Flanders (FWO), during the conduct of the study (as declared in the acknowledgments section).

Please refer to the accompanying [ICMJJE disclosure](#) forms for further details.

Authors' contributions

Bram Vrancken and Lize Cuypers designed and developed the phylogenetic analysis pipeline, performed the phylogeographic analyses and wrote subsequent drafts of the manuscript. Natalia Chueca and Ana Belen Pérez were responsible for performing all HCV sequencing experiments, and both assisted in writing the manuscript. Joaquin Anton-Basantas, Alberto de la Iglesia, Javier Fuentes, Juan Antonio Pineda, Francisco Téllez, Enrique Bernal, Pilar Rincón, Miguel Angel Von Wichman, Ana Fuentes, Francisco Vera, Antonio Rivero-Juárez, Miguel Jiménez provided samples from their clinical centre to be analysed within this study, and assisted in writing the manuscript. Anne-Mieke Vandamme provided substantial support to the phylogenetic computations and assisted extensively in writing the manuscript. Federico Garcia supervised the design of the analyses, the sequencing experiments and assisted extensively in writing the manuscript. None of the funding agencies were involved in the design of the study, nor in the collection, analysis and interpretation of the data, the writing of the manuscript and the decision to submit the manuscript for publication.

Acknowledgments

The authors wish to thank Aida Selfa, Jose de Juan Ramirez, Juan Carlos Alados, Mar Masiá, María José Rios, Antonio Collado, Jesús Santos, Miguel García del Toro, Juan Manuel Pascasio, Jose Miguel Rosales-Zabal, Magdalena Lara, Teresa Aldamiz and Silvia Garcia-B as they provided samples from their clinical centre to be analysed within this study. The Ethics Committee of the San Cecilio Hospital in Granada approved the study.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2019.08.010>.

References

Author names in bold designate shared co-first authorship

- [1] Marshall AD, Pawlotsky JM, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. *J Hepatol* 2018;69:1188–1196.
- [2] Lazarus JV, Safreed-Harmon K, Stumo SR, Jauffret-Roustide M, Maticic M, Reic T, et al. Restrictions on access to direct-acting antivirals for people who inject drugs: the European Hep-CORE study and the role of patient groups in monitoring national HCV responses. *Int J Drug Policy* 2017;47:47–50.
- [3] **Robaey G, Bielen R**, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. *J Hepatol* 2016;65:1094–1103.
- [4] Macías J, Morano LE, Téllez F, Granados R, Rivero-Juárez A, Palacios R, et al. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. *J Hepatol* 2019;71:45–51.
- [5] **Cuypers L, Vrancken B, Fabeni L**, Marascio N, Cento V, Di Maio VC, et al. Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy. *BMC Evol Biol* 2017;17:70.
- [6] Al-Qahtani AA, Baele G, Khalaf N, Suchard MA, Al-Anazi MR, Abdo AA, et al. The epidemic dynamics of hepatitis C virus subtypes 4a and 4d in Saudi Arabia. *Sci Rep* 2017;7:44947.
- [7] Aguilera A, Navarro D, Rodríguez-Frias F, Viciana I, Martínez-Sapiña AM, Rodríguez MJ, et al. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000–2015 period (the GEHEP 005 study). *J Viral Hepat* 2017;24:725–732.
- [8] **Pérez AB, Vrancken B**, Chueca N, Aguilera A, Reina G, García-del Toro M, et al. Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain. *Eurosurveill* 2019;24.
- [9] European Liver Patients' Association. The 2016 Hep-CORE report: Monitoring the implementation of hepatitis B and C policy recommendations in Europe. 2017. Available from: <http://elipa-info.org/index.php/project/hep-core-study>.
- [10] Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. *Clin Infect Dis* 2013;57:1014–1020.
- [11] Ministry of Health, Social Services and Equality: Office of the secretary for Health and Consumer Affairs. Strategic plan for tackling Hepatitis C in the Spanish national health system. 2015, May 21.
- [12] Polaris Observatory. Center for Disease Analysis. Available from: <http://cdafound.org/polaris/>.

Bram Vrancken^{1,*,*}

Lize Cuypers^{1,*,*}

Ana Belen Pérez²

Natalia Chueca²

Joaquin Anton-Basantas³

Alberto de la Iglesia⁴

Javier Fuentes⁵

Juan Antonio Pineda⁶

Francisco Téllez⁷

Enrique Bernal⁸

Pilar Rincón⁶

Miguel Angel Von Wichman⁹

Ana Fuentes²

Francisco Vera¹⁰

Antonio Rivero-Juárez¹¹

Miguel Jiménez¹²

Anne-Mieke Vandamme^{1,13}

Federico García²

¹KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Leuven, Belgium

²Clinical Microbiology, University Hospital San Cecilio, Research Institute Ibs, Granada, Spain

³Centro Penitenciario, Albolote, Granada, Spain

⁴Clinical Microbiology, Hospital Juan Ramón Jiménez, Huelva, Spain

⁵Hepatology Unit, Hospital Miguel Servet, Zaragoza, Spain

⁶Infectious Diseases Unit, University Hospital of Valme, Sevilla, Spain

⁷Infectious Diseases Unit, University Hospital of Puerto Real, Cádiz, Spain

⁸Infectious Diseases, University Hospital Reina Sofía, Murcia, Spain

⁹Infectious Diseases Unit, University Hospital Donostia, San Sebastian, Spain

¹⁰Infectious Disease Unit, University Hospital Santa Lucía, Cartagena, Murcia, Spain

¹¹Infectious Diseases Unit, University Hospital Reina Sofía, Córdoba, Spain

¹²Hepatology Unit, Hospital Carlos Haya, Málaga, Spain

¹³Center for Global Health and Tropical Medicine, Microbiology Unit, Institute of Hygiene and Tropical Medicine, University Nova Lisbon, Lisbon, Portugal

*Corresponding authors. Address: KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Leuven, Belgium. LC: Tel.: +32 16 32 11 76 or BV: +32 16 37 44 00.

E-mail addresses: bram.vrancken@kuleuven.be (B. Vrancken)
lize.cuyppers@kuleuven.be (L. Cuyppers)

These first authors contributed equally to this article.



Reply to: “Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes”

To the Editor:

We appreciate the interest and comments by Vrancken *et al.* They had previously found that the most prevalent HCV genotype in Spain, genotype 1a, was linked to transmission networks outside the country.¹ Specifically, the origin of those strains could be traced to a number of European countries, including France, Germany and Italy among others.¹ In their letter, Vrancken *et al.* expand their data to HCV genotype 3a, most frequently found among people who inject drugs (PWID) in Spain. This is very relevant information. In our paper, we showed that PWID with and without opiate agonist therapy can achieve high sustained virological response rates with direct-acting antiviral combinations. However, the overall efficacy of direct-acting antivirals in active drug users is lower, mainly due to losses to follow-up. Efforts to reduce their risk of abandoning follow-up are needed to reach HCV elimination targets in Spain. Another potential threat for the elimination efforts in Spain is stressed by Vrancken *et al.* An increasing number of HCV genotype 1a¹ and 3a infections are being introduced to Spain from the rest of Europe, essentially through drug use networks. Thus, HCV elimination plans should be developed with a broader perspective than the national level. Otherwise, successful reductions in

the burden of HCV infection in Spain could be counteracted by waves of imported infections.

Conflict of interest

Please refer to the accompanying ICMJE disclosure forms for further details.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2019.09.002>.

References

- [1] Pérez AB, Vrancken B, Chueca N, Aguilera A, Reina G, García-del Toro M, *et al.* Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain. *Eurosurveill* 2019;24.

Juan Macías
Infectious Diseases and Microbiology Unit,
Hospital Universitario de Valme, Sevilla, Spain
E-mail address: jmacias@cica.es



Assessment of liver phenotype in adults with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype)

To the Editor:

We would like to congratulate Clark *et al.* for their pioneering work characterizing histological liver injury in patients with the classic severe alpha-1 antitrypsin (AAT) deficiency (genotype Pi*ZZ).¹ The Pi*ZZ genotype is seen in 1:3,000 Caucasians and the associated liver disease is greatly understudied despite

the fact that it is more frequent than several well-established liver disorders such as autoimmune hepatitis or primary sclerosing cholangitis.^{2,3} While Clark *et al.* greatly enhanced our understanding of the clinical, biochemical and histological liver phenotype of these individuals, we would like to further discuss the following topics: (i) a high occurrence of liver steatosis in